The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2005-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1463-1326.2004.00374.xPMID 15642077
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.

  2003cited by this paper
• Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats

  2003cited by this paper
• Peripheral, but not central, administration of adiponectin reduces visceral adiposity and upregulates the expression of uncoupling protein in agouti yellow (Ay/a) obese mice.

  2003cited by this paper
• Adiponectin represents an independent cardiovascular risk factor predicting serum HDL‐cholesterol levels in type 2 diabetes

  2003cited by this paper
• Diagnosis, prevention, and intervention for the metabolic syndrome.

  2003cited by this paper
• The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.

  2003cited by this paper
• Globular Adiponectin Protected ob/ob Mice from Diabetes and ApoE-deficient Mice from Atherosclerosis*

  2003cited by this paper
• Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.

  2003cited by this paper
• Effect of diet on adipose tissue and skeletal muscle VLDL receptor and LPL: implications for obesity and hyperlipidemia.

  2002cited by this paper
• Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population.

  2002cited by this paper
• Association of obesity, diabetes, serum lipids and blood pressure regulates insulin action.

  2002cited by this paper
• The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

  2001cited by this paper
• Obesity and Cardiovascular Disease Risk: Research Update

  2001cited by this paper
• Leptin-regulated endocannabinoids are involved in maintaining food intake

  2001cited by this paper
• Endogenous glucose production is inhibited by the adipose-derived protein Acrp30.

  2001cited by this paper
• Reversibility of Chronic Experimental Syndrome X by Diet Modification

  2001cited by this paper
• Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice.

  2001cited by this paper
• Obesity as a medical problem

  2000cited by this paper
• Effect of diet on fat cell size and hormone-sensitive lipase activity.

  1999cited by this paper
• Obesity as a risk factor for cardiovascular disease.

  1999cited by this paper
• SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset.

  1998cited by this paper
• Obesity: a time bomb to be defused.

  1998cited by this paper
• Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.

  1998cited by this paper
• Diet-induced obese mice develop peripheral, but not central, resistance to leptin.

  1997cited by this paper
• Leptin levels reflect body lipid content in mice: Evidence for diet-induced resistance to leptin action

  1995cited by this paper
• Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects

  1995cited by this paper
• Caloric Restriction Per Se Is a Significant Factor in Improvements in Glycemic Control and Insulin Sensitivity During Weight Loss in Obese NIDDM Patients

  1994cited by this paper
• SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

  1994cited by this paper

• The endocannabinoidomes: Pharmacological redundancy and promiscuity, and multi-kingdom variety of sources and molecular targets.

  2025cites this paper
• Investigating the alterations of endocannabinoidome signaling in the human small intestine in the context of obesity and type 2 diabetes

  2024cites this paper
• Inhibition of the endocannabinoid system reverses obese phenotype in aged mice and partly restores skeletal muscle function.

  2023cites this paper
• Association between the FAAH C385A variant (rs324420) and obesity-related traits: a systematic review

  2023cites this paper
• Role of the Endocannabinoid System in Metabolic Control Processes and in the Pathogenesis of Metabolic Syndrome: An Update

  2023influential citation
• Co-administration of rimonabant prevents glucose intolerance in Sprague-Dawley rats treated chronically with lopinavir/ritonavir and zidovudine: an experimental study design

  2023cites this paper
• Sex differences in endocannabinoids during 3 years of Mediterranean diet intervention: Association with insulin resistance and weight loss in a population with metabolic syndrome

  2022cites this paper
• Cannabinoids and PPAR Ligands: The Future in Treatment of Polycystic Ovary Syndrome Women with Obesity and Reduced Fertility

  2022cites this paper
• Bioconverted Fruit Extract of Akebia Quinata Exhibits Anti-Obesity Effects in High-Fat Diet-Induced Obese Rats

  2022cites this paper
• Role of the Endocannabinoid System in the Adipose Tissue with Focus on Energy Metabolism

  2021cites this paper
• Metabolic and inflammatory functions of cannabinoid receptor type 1 are differentially modulated by adiponectin

  2021cites this paper
• Circadian misalignment of the 24-hr profile of endocannabinoid 2-arachidonoylglycerol (2-AG) in obese adults.

  2020cites this paper
• Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide).

  2020cites this paper
• Naturally Occurring Cannabinoids and their Role in Modulation of Cardiovascular Health

  2020cites this paper
• Cannabinoid-sensitive receptors in cardiac physiology and ischaemia.

  2020cites this paper
• Cannabis effects on lipoproteins

  2019cites this paper
• Effect of CB1-Antagonist (AM251) on Metabolic Syndrome (Prophylactic and Therapeutic)

  2018cites this paper
• Adipokines as therapeutic targets in breast cancer treatment

  2018cites this paper
• Mechanisms of gustatory perception of dietary lipids : cross-talk with bitter taste and endocannabinoid receptors

  2018cites this paper
• Cannabinoids for Treating Cardiovascular Disorders: Putting Together a Complex Puzzle

  2018cites this paper
• Role of Cannabinoid Receptor Type 2 (CB2) in Late Stage Atherosclerosis

  2017cites this paper
• Anti-obesity effect of robusta fermented with Leuconostoc mesenteroides in high-fat diet-induced obese mice.

  2017cites this paper
• University of Groningen Metabolic responses to long-term pharmacological inhibition of CB 1-receptor activity in mice in relation to dietary fat composition

  2017cites this paper
• Hypothalamic AMPK as a Regulator of Energy Homeostasis

  2016cites this paper
• Evaluation of a Mathematical Model of Rat Body Weight Regulation in Application to Caloric Restriction and Drug Treatment Studies

  2016cites this paper
• Anandamide and its metabolites: what are their roles in the kidney?

  2016cites this paper
• Cannabinoids and appetite (dys)regulation

  2015cites this paper
• Assessment of the pectolinarin content and the radical scavenging-linked antiobesity activity of Cirsium setidens Nakai extracts

  2015cites this paper
• Dietary linoleic acid elevates the endocannabinoids 2-AG and anandamide and promotes weight gain in mice fed a low fat diet

  2015cites this paper
• Acute and chronic systemic CB1 cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive (mRen2)27 rats

  2014influential citation
• Blood pressure regulation by the endocannabinoid system in conditions associated with hypertension

  2014cites this paper
• The role of endocannabinoid system in the obesity induced atherogenesis : what are the possible mechanism/s involved ?

  2014cites this paper
• 18β-glycyrrhetinic acid attenuates anandamide-induced adiposity and high-fat diet induced obesity.

  2014cites this paper
• Dietary Linoleic Acid Elevates the Endocannabinoids 2-AG and Anandamide and Promotes Weight Gain in Mice Fed a Low Fat Diet

  2013cites this paper
• Genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) and their influence on anthropometric parameters and metabolic parameters under a high monounsaturated vs. high polyunsaturated fat hypocaloric diets.

  2013cites this paper
• The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity

  2013cites this paper
• Islet Cannabinoid Receptors: Cellular Distribution and Biological Function

  2013cites this paper
• Insulin signalling depends on the endocannabinoid system in the brain

  2013cites this paper
• Endocannabinoids and obesity.

  2013cites this paper
• Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.

  2013cites this paper
• Fat to treat fat: emerging relationship between dietary PUFA, endocannabinoids, and obesity.

  2013cites this paper
• ORIGINAL ARTICLE The cannabinoid D 9 -tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity

  2013cites this paper
• The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release

  2013cites this paper
• 6-Alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds.

  2013cites this paper
• Implication des neurones exprimant NUCB2/nesfatine-1 dans la régulation de l'homéostasie énergétique

  2013cites this paper
• Dietary linoleic acid induces obesity through excessive endocannabinoid activity

  2012cites this paper
• Diabetes in an Undergraduate Class

  2012cites this paper
• Rimonabant

  2012cites this paper
• Kannabinoid tip 1 reseptör (CB1) ve terapötik yaklaşımlara genel bakış-II

  2012cites this paper
• Adiponectin and cardiovascular disease: mechanisms and new therapeutic approaches.

  2012cites this paper
• The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: potential implications for the treatment of obesity

  2012cites this paper
• A Novel Monoclonal Antibody Against Cannabinoid Receptor 1

  2012cites this paper
• Pleiotropic effects of rimonabant and simvastatin on obesity associated multiple metabolic risk factors in rats.

  2012cites this paper
• Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity

  2012cites this paper
• Role of G1359A polymorphism of the cannabinoid receptor gene on weight loss and adipocytokines levels after two different hypocaloric diets.

  2012cites this paper
• Does rimonabant independently affect free fatty acid and glucose metabolism?

  2012cites this paper
• Selective cannabinoid-1 receptor blockade benefits fatty acid and triglyceride metabolism significantly in weight-stable nonhuman primates.

  2012cites this paper
• Antagonism of peripheral hepatic cannabinoid receptor‐1 improves liver lipid metabolism in mice: Evidence from cultured explants

  2012cites this paper
• Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders

  2012cites this paper
• NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.

  2012cites this paper
• A Novel and Practical Synthesis of Rimonabant Hydrochloride

  2012cites this paper
• REGULACIÓN DE LA EXPRESIÓN Y FUNCIÓN DEL RECEPTOR GPR55 EN LA HOMEOSTASIS ENERGÉTICA Y METABÓLICA

  2012cites this paper
• Addition of a low dose of rimonabant to orlistat therapy decreases weight gain and reduces adiposity in dietary obese rats

  2012cites this paper
• Central Endocannabinoid Signaling Regulates Hepatic Glucose Production and Systemic Lipolysis

  2011cites this paper
• Safety evaluation and treatment affect of LY2190416, a CB-1 antagonist/inverse agonist in growing beagle dogs.

  2011cites this paper
• Effets du blocage des récepteurs CB1 par le rimonabant sur la fonction mitochondriale hépatique

  2011cites this paper
• Plasma and Liver Lipidomics Response to an Intervention of Rimonabant in ApoE*3Leiden.CETP Transgenic Mice

  2011cites this paper
• Retinol‐binding protein 4 : a possible role in cardiovascular complications

  2011cites this paper
• Influence of G1359A polymorphism of the cannabinoid receptor gene on anthropometric parameters and insulin resistance in women with obesity.

  2011cites this paper
• Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes.

  2011cites this paper
• Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice.

  2011cites this paper
• Investigations of the endocannabinoid system in adipose tissue: effects of obesity/ weight loss and treatment options.

  2011cites this paper
• Effect of Fruit and Vegetable Intake on Oxidative Stress and Dyslipidemia Markers in Human and Animal Models

  2011cites this paper
• The Central Cannabinoid CB1 Receptor Is Required for Diet‐Induced Obesity and Rimonabant's Antiobesity Effects in Mice

  2011cites this paper
• Roles of G1359A polymorphism of the cannabinoid receptor gene (CNR1) on weight loss and adipocytokines after a hypocaloric diet.

  2011cites this paper
• Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas.

  2011cites this paper
• Acute cannabinoid receptor type 1 (CB1R) modulation influences insulin sensitivity by an effect outside the central nervous system in mice

  2011cites this paper
• The endocannabinoid arachidonylethanolamide attenuates aspects of lipopolysaccharide-induced changes in energy intake, energy expenditure and hypothalamic Fos expression.

  2011cites this paper
• Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice

  2011cites this paper
• Relation of G1359A polymorphism of the cannabinoid receptor (CB1) gene with metabolic syndrome by ATP III classification

  2011cites this paper
• Effect of the Cannabinoid Receptor‐1 Antagonist Rimonabant on Inflammation in Mice With Diet‐Induced Obesity

  2011cites this paper
• Endocannabinoids in liver disease

  2011cites this paper
• CB 1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice Short running title : CB 1 antagonism in diet-induced obese mice

  2010cites this paper
• Impact du système endocannabinoïdien sur la physiologie de l'obésité : effets de l'antagonisme des récepteurs CB1 sur le métabolisme glucido-lipidique de la souris obèse

  2010cites this paper
• Cannabinoid 1 receptor blockade reduces atherosclerosis with enhances reverse cholesterol transport.

  2010cites this paper
• Metabolic responses to long-term pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition

  2010cites this paper
• Endocannabinoid (EC) Receptor, CB1, and EC Enzymes' Expression in Primary Adipocyte Cultures of Lean and Obese Pre-pubertal Children in Relation to Adiponectin and Insulin

  2010cites this paper
• CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese Mice

  2010cites this paper
• [A role for the endocannabinoid system in obesity].

  2010cites this paper
• Transcriptional Regulation of Cannabinoid Receptor-1 Expression in the Liver by Retinoic Acid Acting via Retinoic Acid Receptor-γ*

  2010cites this paper
• Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome.

  2010cites this paper
• A Selective Cannabinoid-1 Receptor Antagonist, PF-95453, Reduces Body Weight and Body Fat to a Greater Extent than Pair-Fed Controls in Obese Monkeys

  2010cites this paper
• New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?

  2010cites this paper
• Expression and function of cannabinoid receptors in mouse islets

  2010cites this paper
• Effects of chronic nicotine on food intake and anxiety-like behaviour in CB(1) knockout mice.

  2010cites this paper
• Leptin as a potential therapeutic target for breast cancer prevention and treatment

  2010cites this paper
• Variants in the CNR1 and the FAAH Genes and Adiposity Traits in the Community

  2009cites this paper
• Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs.

  2009cites this paper
• Métabolisme énergétique mitochondrial dans le développement de la stéatose hépatique

  2009cites this paper
• The dysregulation of the endocannabinoid system in diabesity—a tricky problem

  2009cites this paper